| [1] |
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet, 2019, 393(10166):31-39.
|
| [2] |
«改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议»工作组. 改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J]. 中国循环杂志, 35(3):231-238.
|
| [3] |
杨金凤,贾辛未,苏伟,等. 钠-葡萄糖协同转运蛋白2抑制剂对心血管保护作用机制的研究进展[J]. 临床心血管病杂志,2020,36(2):107-110.
|
| [4] |
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128.
|
| [5] |
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)[J]. Circulation, 2018, 137(4):323-334.
|
| [6] |
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24):2295-2306.
|
| [7] |
McMurray J, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21):1995-2008.
|
| [8] |
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2022, 79(17):1757-1780.
|
| [9] |
Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial[J]. Circulation, 2021, 143(4):326-336.
|
| [10] |
Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial[J]. Circulation, 2021, 144(16):1284-1294.
|
| [11] |
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385(16):1451-1461.
|
| [12] |
Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes mellitus and heart failure, a scientific statement from the American Heart Association And Heart Failure Society of America[J]. J Card Fail, 2019, 25(8):584-619.
|
| [13] |
Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(12):1180-1193.
|
| [14] |
Gaborit B, Ancel P, Abdullah AE, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study[J]. Cardiovasc Diabetol, 2021, 20(1):57.
|
| [15] |
Lee DM, Battson ML, Jarrell DK, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice[J]. Cardiovasc Diabetol, 2018, 17(1):62.
|
| [16] |
Ganbaatar B, Fukuda D, Shinohara M, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice[J]. Eur J Pharmacol, 2020, 875:173040.
|
| [17] |
Correale M, Petroni R, Coiro S, et al. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?[J]. Heart Fail Rev, 2022, 27(4):1147-1163.
|
| [18] |
Yanai H, Katsuyayama H. A possible mechanism for renoprotective effect of sodium-glucose cotransporter 2 inhibitor: elevation of erythropoietin production[J]. J Clin Med Res, 2017, 9(2):178-179.
|
| [19] |
Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects[J]. Circulation, 2019, 139(17):1985-1987.
|
| [20] |
Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial[J]. Cardiovasc Diabetol, 2018, 17(1):5.
|
| [21] |
Sattar N, McLaren J, Kristensen SL, et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?[J]. Diabetologia, 2016, 59(7):1333-1339.
|
| [22] |
Verma S, McMurray J, Cherney D. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure[J]. JAMA Cardiol, 2017, 2(9):939-940.
|
| [23] |
Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes[J]. Diabetes Obes Metab, 2013, 15(9):853-862.
|
| [24] |
Sano M, Takei M, Shiraishi Y, et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys[J]. J Clin Med Res, 2016, 8(12):844-847.
|
| [25] |
Lopaschuk GD, Ussher JR, Folmes CD, et al. Myocardial fatty acid metabolism in health and disease[J]. Physiol Rev, 2010, 90(1):207-258.
|
| [26] |
Sowton AP, Griffin JL, Murray AJ. Metabolic profiling of the diabetic heart: toward a richer picture[J]. Front Physiol, 2019, 10:639.
|
| [27] |
Neubauer S. The failing heart--an engine out of fuel[J]. N Engl J Med, 2007, 356(11):1140-1151.
|
| [28] |
Lopaschuk GD, Verma S. Empagliflozin's fuel hypothesis: not so soon[J]. Cell Metab, 2016, 24(2):200-202.
|
| [29] |
Russell RR, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate[J]. J Clin Invest, 1991, 87(2):384-390.
|
| [30] |
Kanamori H, Takemura G, Goto K, et al. Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes[J]. Autophagy, 2015, 11(7):1146-1160.
|
| [31] |
Karbasforooshan H, Karimi G. The role of SIRT1 in diabetic cardiomyopathy[J]. Biomed Pharmacother, 2017, 90:386-392.
|
| [32] |
Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action[J]. Diabetes Care, 2020, 43(3):508-511.
|
| [33] |
Hawley SA, Ford RJ, Smith BK, et al. The Na+/Glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels[J]. Diabetes, 2016, 65(9):2784-2794.
|
| [34] |
Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and-independent mechanisms[J]. Sci Rep, 2018,8(1):5276.
|